1. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin,
antioxidant vitamins, or the combination for the prevention of coronary disease.
N Engl J Med 2001;345(22):1583-92
2. American Diabetes Association Position Statement. Dyslipidemia
management in **s with diabetes. Diabetes Care 2004;27(Suppl 1):S68-71
3. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the
Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a
double-blind, placebo-controlled study of extended-release niacin on
atherosclerosis progression in secondary prevention patients treated with
statins. Circulation 2004;110(23):3512-7
4. Guyton JR. Extended-release niacin for modifying the lipoprotein
profile. Expert Opin Pharmacother 2004;5(6):1385-98
5. Michael P. Kane, Pharm.D., Robert A. Hamilton, Pharm.D., Elizabeth
Addesse, Pharm.D.,et al. Cholesterol and Glycemic Effects of Niaspan in Patients
with Type 2 Diabetes. Pharmacotherapy .2001;21(12):1473-1478
6. Gupta EK, Ito MK. Lovastatin and extended-release niacin combination
product:the first drug combination for the management of hyperlipidemia. Heart
Dis. 2002;4(2):124-37
7. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of
once-daily niacin for the treatment of dyslipidemia associated with type 2
diabetes: results of the assessment of diabetes control and evaluation of the
efficacy of niaspan trial. Arch Intern Med 2002 Jul 22;162(14):1568-76
8. Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and
statin-niacin combination therapy in dyslipidemic patients at high risk for
cardiovascular events. Am J Cardiol 2002 Feb 15;89(4):390-4
9. Duvall WL, Blazing MA, Saxena S, et al. Targeting cardiovascular risk
associated with both low density and high density lipoproteins using
statin-niacin combination therapy. J Cardiovasc Risk 2002 Dec;9(6):339-47
10. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a
once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J
Cardiol 2002 Mar 15;89(6):672-8
11. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin
extended-release/lovastatin with standard doses of atorvastatin and simvastatin
(the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation
[ADVOCATE]). Am J Cardiol 2003 Mar 15;91(6):667-72
12.Yeshurun D, Hamood H, Morad N, Naschitz J. Acipimox (Olbetam) as a secondary
hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia Harefuah
2000 Apr 16;138(8):650-3